Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
about
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaTreatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaA systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndromeExploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infectionIncreased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature.Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Small-molecule factor D inhibitors targeting the alternative complement pathway.Applying complement therapeutics to rare diseases.Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Blood consult: paroxysmal nocturnal hemoglobinuria and its complicationsPolyphosphate suppresses complement via the terminal pathway.C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotypeReincarnation of ancient links between coagulation and complement.From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe.Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen.
P2860
Q24193045-D19A4CB8-44F3-41A0-88BE-F4F5BB0FC397Q28390806-CE54D835-8FFC-499B-B33E-6F10925DDCDFQ28661698-1EE3642E-05A5-4F7F-8962-F9809A94D3DFQ33414227-ED003006-E12E-4630-84C8-437EC9BF5E03Q34257818-3E7F0009-8953-4EC4-B9DB-8EBCE4D1C1BEQ35155748-34CAE398-5660-489A-AE24-0A05A05DB203Q35236103-73B49A7D-E6AC-4E32-B494-AF4F32DE907FQ35252156-2D112224-F66A-491B-B85E-0C04DF31E23DQ36172936-141DD5FD-120C-43D8-A3C7-83C0E43B481DQ36315497-192B5584-6F07-472E-B7AB-A81EA0491CE2Q36460034-D6A684DB-1304-4C05-AE06-6C8FFB49EF86Q37235669-5013235B-E7CD-470D-8597-F311E05660C0Q37535268-A5F2B4EC-5058-41E7-A123-E97DEC5ED4A8Q37615906-345E98B3-E637-45F4-B0D0-F1B20D0EA11DQ37617110-ADF2CF7C-CE4F-4F3A-9B53-5171BDA617C9Q38543278-F17D8C07-32B7-414D-9265-9492CE459057Q38879877-0EF8079B-8163-4367-8E56-24A0AF00D54EQ41430132-3A93CDF0-5A44-4D8A-9AA3-C19CC3FD3DB2Q41462651-901C0A86-9C02-4DFF-B575-D4C7BAFF4E45Q55252352-0A59D560-024C-4B08-93E0-E7FF6477CB5E
P2860
Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Paroxysmal nocturnal hemoglobi ...... vel anticomplement strategies.
@en
type
label
Paroxysmal nocturnal hemoglobi ...... vel anticomplement strategies.
@en
prefLabel
Paroxysmal nocturnal hemoglobi ...... vel anticomplement strategies.
@en
P1476
Paroxysmal nocturnal hemoglobi ...... vel anticomplement strategies.
@en
P2093
Antonio M Risitano
P304
P356
10.1007/978-1-4614-4118-2_10
P407
P577
2013-01-01T00:00:00Z